Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib (GLPG0634) PK in Subjects with Renal Impairment
NCT02084199Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of filgotinib in rheumatoid arthritis (RA), ulcerative colitis (UC) and Crohn's disease (5 arms), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration at Day 17 and Area under the plasma drug concentration-time curve over 24 hours at Day 17. Started Mar 2014; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02084199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084199.